# Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway

> **NCT02598895** · PHASE2 · COMPLETED · sponsor: **University of Washington** · enrollment: 14 (actual)

## Conditions studied

- Castration Levels of Testosterone
- Castration-Resistant Prostate Carcinoma
- Metastatic Prostate Carcinoma
- Prostate Carcinoma Metastatic in the Bone
- PSA Progression
- Stage IV Prostate Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Docetaxel
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02598895
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-26
- **Primary completion:** 2021-09-14
- **Final completion:** 2021-09-14
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2022-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02598895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02598895, "Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02598895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*